Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Panax Ginseng | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 200-400 mg/day of standardized extract (4-7% ginsenosides, typically G115 brand) or 1-2 g/day of dried root | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning on an empty stomach or with food. Avoid evening dosing due to mild stimulatory effects. Acute cognitive effects noted within 1-4 hours of dosing. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Traditionally cycled 2-3 weeks on, 1-2 weeks off. Long-term continuous use exceeding 3 months is debated. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | moderate_human | moderate_human |
Ginsenosides (primarily Rg1, Rb1, Re) are amphipathic steroidal saponins that modulate multiple neurotransmitter systems: enhancement of cholinergic transmission via increased acetylcholine synthesis and release; activation of PI3K/Akt and CREB/BDNF signaling pathways to promote neurogenesis and synaptic plasticity; attenuation of neuroinflammation through Keap1/Nrf2 signaling and suppression of the NF-kB/NLRP3 inflammasome axis; and regulation of the HPA axis to buffer cortisol response to stress. Protopanaxadiol and protopanaxatriol ginsenosides have opposing modulatory effects on GABA-A receptors.
200-400 mg/day of standardized extract (4-7% ginsenosides, typically G115 brand) or 1-2 g/day of dried root
Morning on an empty stomach or with food. Avoid evening dosing due to mild stimulatory effects. Acute cognitive effects noted within 1-4 hours of dosing.
Traditionally cycled 2-3 weeks on, 1-2 weeks off. Long-term continuous use exceeding 3 months is debated.
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →